Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.

Tretinoin can irritate seborrheic dermatitis, but using it with a moisturizer on calm skin may help. Parallel Health's skin microbiome testing and phage therapy are suggested for persistent issues.

The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

The conclusion of the conversation is that CosmeRna may not be an effective treatment for hair loss compared to topical minoxidil 2%. It is suggested to wait for more reviews before purchasing it.

Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.

The user is using minoxidil, finasteride, dutasteride, and clobetasol, along with needling, to combat hair loss. They are considering stopping treatment if no improvement is seen.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

Treating hair loss with various remedies, such as Cetirizine and the Big3 complex (minoxidil, finasteride, and RU58841), which have properties like adipogenic, anti-fibrotic and anti-inflammatory. References to research studies are also included.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

Caffeine might raise stress hormones, potentially worsening hair loss. Telogen effluvium is often misattributed to minor stressors rather than significant life events.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

The conversation discusses the potential of topical cetirizine (Zyrtec) for hair growth in comparison to minoxidil, noting cetirizine's ability to reduce prostaglandin D2, which inhibits hair growth. Users share mixed experiences with cetirizine for allergies and scalp health, and there's a mention of the risk of dementia with long-term antihistamine use.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

User ItchyRaccoon experienced significant hair loss reduction using Eucapil after trying low-dose topical finasteride with no results. Some replies mention that shed hair counts are not reliable indicators of hair loss progression or regression.

The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.

The user is asking about the effectiveness of tretinoin 0.025% for hair loss, noting significant beard growth since using it for acne. They are considering adding it to their hair loss treatment regimen.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.